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Abstract
We performed a mutational analysis of the 19 disintegrin-metalloproteinases (ADAMs)genes in
human cutaneous metastatic melanoma and identified eight to be somatically mutated in 79
samples, affecting 34% of the melanoma tumors analyzed. Functional analysis of the two
frequently mutated ADAM genes, ADAM29 and ADAM7 demonstrated that the mutations affect
adhesion of melanoma cells to specific extracellular matrix proteins and in some cases increase
their migration ability. This suggests that mutated ADAM genes could play a role in melanoma
progression.
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INTRODUCTION
The matrix metalloproteinase (MMP) proteolytic enzymes have recently been shown to be
frequently mutated in melanoma (Palavalli, et al., 2009). The MMPs are only one family
within a superfamily of zinc-based proteinases, the metzincins (Stocker and Bode, 1995).
Another family of metzincins is the ADAMs (a disintegrin and metalloproteinase) which are
membrane anchored glycoproteins with several biological functions encompassing cell
adhesion, cell fusion and signaling. About half of the ADAMs have a consensus
metalloproteinase catalytic sequence, giving them proteolytic activity, whereas the rest have
cell adhesion roles. Well characterized ADAM family members include ADAM17 (TACE)
which causes ectodomain shedding of various membrane-associated molecules including
TNF-α and EGF-related ligands (Peschon, et al., 1998), as well as ADAM10 which has been
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shown to act via the Notch pathway (Qi, et al., 1999) and through shedding of ephrins
(Hattori, et al., 2000). Although the function of some of the ADAMs has been characterized,
the function of most family members and their involvement in cancer is as yet unknown
(Blobel, 2005; Schlondorff and Blobel, 1999).
Several studies suggest a direct role of ADAM family in human cancer development and
progression. For example, ADAM17 is an upstream regulator of the EGF signaling pathway,
one of the most commonly altered signal transduction pathways in cancer. Additionally, the
presence of distinct somatic mutations in several members of the ADAM family further
suggests a direct involvement of these genes in cancer genesis (Dalgliesh, et al., 2010;
Parsons, et al., 2008; Pleasance, et al., 2010; Sjoblom, et al., 2006; TCGA, 2008). However,
previous reports investigating the extent of ADAM mutations in cancer are incomplete as
they either did not investigate the entire ADAM gene family or were limited to particular
cancer types (Sjoblom, et al., 2006; Wood, et al., 2007).
In this study, we systematically analyzed the entire ADAM gene family in a large panel of
human melanomas. Melanoma is the most common fatal skin cancer and despite years of
research, metastatic disease has a dismal prognosis. The median patient survival is six
months following diagnosis of late-stage disease, with fewer than 5% surviving five years
(Jemal, et al., 2009). Identification of genes affected by somatic mutations in metastatic
melanomas should provide new opportunities for clinical intervention. Our comprehensive
genetic study identified two frequently mutated ADAM genes, ADAM29 (MIM# 604778)
and ADAM7 (MIM# 607310).
Functional analysis of a subset of mutations identified in ADAM29 showed them to increase
their adhesion to collagen I, II and IV. In contrast, analysis of ADAM7 mutations showed
reduced cell adhesion to collagen IV and laminin and increased melanoma cell migration.
Our study is the first comprehensive mutational analysis of the ADAM family in human
cancer and provides evidence for the association of ADAM in melanoma tumorigenesis.
MATERIALS AND METHODS
Tumor Tissues
A panel of pathology-confirmed metastatic melanoma tumor resections, paired with
apheresis-collected peripheral blood mononuclear cells, was collected from 79 patients
enrolled in IRB-approved clinical trials at the Surgery Branch of the National Cancer
Institute. Pathology-confirmed melanoma cell lines were derived from mechanically or
enzymatically dispersed tumor cells, which were subsequently cultured in RPMI 1640 +
10% FBS at 37°C in 5% CO2 for 5–15 passages. Genomic DNA was isolated using DNeasy
Blood & Tissue kit (Qiagen, Valencia, CA).
PCR, sequencing and mutational analysis of melanoma samples
PCR and sequencing was done as previously described (Palavalli, et al., 2009; Prickett, et
al., 2009; Viloria, et al., 2009). The primary phase mutation screen was analyzed using
Consed (Gordon, et al., 1998). Variants were called using Polyphred 6.11 (Bhangale, et al.,
2006) and DIPDetector (Hansen N., unpublished), an indel detector for improved sensitivity
in finding insertions and deletions. Sequence traces of the secondary screen were analyzed
using the Mutation Surveyor software package (SoftGenetics, State College, PA).
In this study all coding exons of the ADAM gene superfamily in 31 melanoma patients were
included into the screen and a total of 401 exons from the ADAM were extracted from
genomic databases (Supp. Table S1). These exons as well as at least 15 intronic bases at
both the 5' and 3' ends including the splicing donor and acceptor sites, were amplified by
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using polymerase chain reaction (PCR) from cancer genomic DNA samples using the
primers listed in Supp. Table S2. Out of the 367 exons amplified, 96% were successfully
sequenced using dye terminator chemistry.
Validation of somatically mutated genes was performed in an additional 48 tumor samples.
A total of 20,098 PCR products, spanning 7Mb of tumor genomic DNA, were generated and
sequenced. Sequence data for each amplicon were evaluated for quality within the target
region. To avoid PCR or sequencing artifacts we re-amplified and re-sequenced amplicons
that had alterations.
The DNA mutation numbering system used in this study was based on cDNA sequence.
Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the
ATG translation initiation codon in the reference sequence, according to journal guidelines
(www.hgvs.org/mutnomen). The initiation codon is codon 1.
Construction of wild-type and mutant ADAM29 and ADAM7 expression vector
Human ADAM7 (NM_003817.2) and ADAM29 (NM_014269.4) were purchased from Open
Biosystems and PCR cloned into the mammalian expression vector pCDF-MCS2-EF1-
Puro™ (Systems Biosciences, Inc., Mountain View, CA) or pCDNA3.1 (−) (Invitrogen,
Molecular Probes) via the XbaI and NotI restriction sites. Flag tag was introduced into 3'
end of the gene. Cloning primers for ADAM7 are: 5' -
GCTGTCTAGAGCCACCATGAAGATGTTACTCCTGCTGCATTGCCTTGGG - 3' and
5' - ATCAGCGGCCGCCTACTTATCGTCGTCATCCTTGTAATCCTTGGCACTTTG -
3'. Cloning primers for ADAM29 are 5'-
GCTGTCTAGAGCCACCATGAAGATGTTACTCCTGCTGCATTGCCTTGGGG - 3' and
5'- ATCAGCGGCCGCCTACTTATCGTCGTCATCCTTGTAATCGGAGGGCGTCA - 3'.
The ADAM7 and ADAM29 mutants were generated using Phusion PCR for site-directed
mutagenesis.
Generation of Mel-STR and A375 stable pooled clones
Mel-STR cells were maintained in RPMI-1640 supplemented with 10% FBS. Cells were
seeded in T175 flasks at 70% confluent the day before transfection. pcDNA3.1(−) empty
vector or ADAM7 (WT, p.H243Y, p.M359I, p.E639K, p.S703N) were transfected into cells
using Fugene6 (Roche, Indianapolis, IN) following manufacturers protocol. 48 hrs after
transfection, cells were selected using normal growth medium supplemented with 300μg/ml
G418.
To make lentivirus for ADAM29 A375 stable pooled clones, pCDF-ADAM29 (WT,
p.E111K, p. S112F, p.S115F, p.E176K, p.I257F, p.G434D, p.E503K) constructs were co-
transfected into HEK 293T cells seeded at 1.5×106 per T75 flask with pVSV-G and
pFIV-34N (kind gifts from Todd Waldman, Georgetown University) helper plasmids using
Fugene6 (Roche, Indianapolis, IN). Virus was harvested 48 hrs after transfection. A375 cells
were seeded at 1.5 × 106 cells per T75 flask 24 hr prior to infection. 24 hrs after infection,
cells were selected using normal growth medium supplemented with 3ng/ml puromycin.
Proliferation assay
Mel-STR or A375 cells were seeded in 96 well plates at 250 cells per well in normal growth
medium and incubated for 13–17 days. Proliferation of cells were monitored every 48 hrs.
Cells were incubated in 50 μl 0.2% SDS/well at 37°C for 2 hrs. 150 μl/well SYBR Green I
solution (1:750 SYBR Green I (Invitrogen-Molecular Probes) diluted in dH20) were added
to cells before analyzing using a BMG Labtech FLOUstar Optima.
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Reverse Transcription PCR
Total RNA was extracted from melanocytes, melanoma cells and pooled clones following
the manufacturer's protocol for RNeasy Mini Kit (Qiagen #74101). Total RNA was eluted in
30 μl DEPC-treated dH20. A total of 1μg of total RNA was used for single strand cDNA
synthesis using a SuperScript III First Strand kit (Invitrogen #18080-051). cDNA was
amplified using the oligo dT20 primer supplied in the kit. PCR primers used for ADAM7
message are 5′-ACACGGAAGGATTTTGATCATGTTG - 3′ and 5′-
GGATTGGCTCAGTCCTTATCTGCTG - 3′., ADAM29 PCR primers are 5'-
GATCTGGACCAATAAAAACCTCATTGTAGTAGATGATGTAAGGAA -3' and 5'-
CATTTTTGATACCACAGTGACCAACACGGTCACCTAAGG - 3'. GAPDH primers
(forward primer: 5′- TGGAAGGACTCATGACCACA - 3′, reverse primer: 5′-
TGCTGTAGCCAAATTCGTTG -3′) were used as a control. The product was then analyzed
on a 1% agarose gel.
Adhesion Assay
Adhesion capacity of different cell pools was analyzed with the ECM Cell Adhesion Array
kit (Colorimetric) (EMD Biosciences, ECM540 96 wells) following manufacturer's
instructions.
Migration assays
Mel-STR ADAM7 stable clones were seeded into migration wells (8.0 μm – BD Biocoat, BD
Biosciences) at 10,000 cells per well in serum-free medium in top chambers and incubated
for 24 hrs. The bottom chamber contain normal growth medium. Migrated cells were fixed
and stained using Hema 3 Stat Pack.
RESULTS
The human ADAM family consists of 19 genes (Supp. Table S1). While previous studies
listed in Supp. Table S3 investigated the ADAM gene family mutational status, results are
not comprehensive. As a few of the ADAM genes were found to be altered in melanoma
previously, we decided to systematically evaluate the mutation status of all the gene family
members in a large panel of cutaneous metastatic melanoma samples. The coding exons of
the ADAMs gene superfamily were genetically evaluated in 31 melanoma patients. To
determine whether a mutation was somatic (i.e., tumor specific) we examined the sequence
of the gene in genomic DNA from normal tissue (derived from blood) of the relevant
patient. This allowed the identification of eight genes containing somatic mutations. Genes
found to have one non-synonymous mutation or more were then further analyzed for
mutations in an additional 48 melanomas. Through this approach, we identified 41
mutations in eight genes, thus affecting 34% of the melanoma tumors analyzed (Table 1).
The observed somatic mutations could either be “driver” mutations, on which tumor growth
is dependent, or “passenger” events that confer no selective advantage to tumor growth. In
the eight genes found to be mutated, 41 non-synonymous and 10 synonymous somatic
mutations were identified, yielding a N:S (non-synonymous: synonymous) ratio of 4.1:1, a
value significantly higher than the N:S ratio of 2:1 predicted for nonselected passenger
mutations (p <0.03) (Sjoblom, et al., 2006), suggesting that many of these are likely to be
“driver” mutations. Most somatic mutations base substitutions in our screen were C>T/G>A
transitions and were significantly greater than other nucleotide substitutions (p <0.002)
(Supp. Figure S1), which is reminiscent of the mutation pattern reported previously caused
by ultraviolet light exposure (Greenman, et al., 2007).
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One of the most frequently mutated genes, ADAM7, harbored two alterations in the same
residue (p.G302E), forming a mini-hotspot. Evaluation of the mutation status of ADAM7 in
commercially available melanoma cell lines revealed two additional mini-hotspots. The
mutation p.H243Y found in the SK-Mel5 melanoma line was also present in the 72T
sample, and the melanoma cell line SK-Mel28 was found to harbor the p.M359I mutation
which was also detected in the 23T melanoma sample. The three mini-hotspots occur within
the same functional reprolysin domain (Supp. Figures S2 and S3A).
Eight of the genes found to be mutated in our melanoma panel were previously found to be
altered in several cancer types (highlighted in Supp. Table S3). Only four of these were
found to be mutated in melanoma. Notably, seven of the previously observed alterations lie
close to the mutations detected in this study. ADAM18 which was formerly found to be
mutated on residue p.T583I in glioma was mutated on residue p.S536L in our melanoma
panel. ADAM28 which was previously reported to harbor a mutation in residue p,D470N in
melanoma was identified to harbor two neighboring somatic mutations (p.G450E and
p.S482F) in our melanoma panel. ADAM19 which was reported to contain the p.L425V
alteration in the disintegrin domain had a p.Q500X alteration in the same domain in our
studies. Finally, the most frequently mutated gene, ADAM29, was previously found to be
mutated in melanoma in the recently published whole genome report by the Sanger Center
(Pleasance, et al., 2010). Importantly, all previously identified mutations (p.V205I, p.C534X
and p.G589E) lie in the same domains as our newly discovered mutations (Table 2 and
Supp. Figure S3).
The clinical information associated with the melanoma tumors containing somatic ADAM
mutations is provided in Supp. Tables S4 and S5. There was no association of the detected
mutation pattern with any of the analyzed clinical or pathological characteristics of the
melanoma patients.
ADAM7 was one of the most frequently mutated ADAM genes, as it was found to be
somatically mutated in over 12% of melanoma cases (Table 1). In addition, taking into
account a background mutation rate in melanoma of 11 mut/Mb (paper under review), the
observed mutations in ADAM7 are significantly different to that expected by chance (p=
1.32E-06). The alterations identified in ADAM7 occurred in residues that are highly
conserved evolutionarily, retaining identity in rat and mouse (Supp. Figure S4).
Furthermore, the identified somatic mutations clustered onto various important functional
domains of the ADAM family (Supp. Figure S3A). While mutations p.P14S, p.R31C,
p.P36S and p.H106Y all occur in the propeptide domain. Mutations p.H243Y, p.G302E and
p.M359I are within the reprolysin domain. To provide a computational estimation of the
effects of the different missense mutations, we used the SIFT (sorting intolerant from
tolerant) algorithm (Ng and Henikoff, 2003). This data is presented in Supp. Table S6 and
shows that at least six of the eleven alterations would affect protein function. Interestingly,
in contrast to melanoma cells, no ADAM7 was found to be expressed in human melanocytes
(Supp. Figure S5). The combination of this data suggests that mutant ADAM7 is likely to
function as a driver in melanoma.
Based on the potential functional relevance of the altered residues in ADAM7, and the fact
that ADAM7 does not have protease activity we chose to clone the two cytoplasmic
mutations p.E639K and p.S703N as well as the p.H243Y and p.M359I mutations for further
studies. To test the effects of these mutations on ADAM7 function we created stable pooled
clones in human melanoma Mel-STR cells (Gupta, et al., 2005) which harbor wild-type
ADAM7 (Supp. Table S7). As seen in Supp. Figure S6A the cell clones expressed similar
levels of wild-type or mutant ADAM7. These clones were then used for further studies. We
first observed that expression of wild-type or mutant ADAM7 did not affect the growth rate
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of Mel-STR cells in tissue culture (Supp. Figure S6B). Then, and because ADAM family
members are known to modulate tumor cell adhesion by interactions with proteins in the
basal lamina (Edwards, et al., 2008), we evaluated whether the mutations in ADAM7
affected its adhesion to different extracellular matrix components. For this purpose, we used
the above described Mel-STR pooled clones expressing wild-type or mutant ADAM7 in an
adhesion assay. This assay revealed that mutant ADAM7 conferred significantly reduced
binding on collagen IV (p.M359I, p.E639K and p.S703N) and laminin-1 (p.H243Y,
p.E639K and p.S703N) compared with the wild-type expressing cells (P < 0.005, t-test)
(Figure 1).
As previous studies reported that reduced adhesion facilitates cell migration (Touab, et al.,
2002; Yamagata, et al., 1989), our finding that cells expressing mutant ADAM7 have
reduced collagen IV and laminin-1 adhesion prompted us to investigate whether these cells
also have increased migration ability. As can be seen in Figure 2A, Mel-STR control cells
migrated through the porous membrane. Interestingly, cells expressing wild-type ADAM7
resulted in > 60% reduction in migrating cells (171 +/− 6.6 versus 70+/− 17.7). When the
ADAM7 mutant expressing cells were tested in the same assay, two mutations (p.E639K
and p.S703N) increased the cell migration capabilities compared to wild-type ADAM7
(122+/− 18.5 and 210 +/− 33.6 P < 0.001, t-test). Based on these results we can conclude
that wild-type ADAM7 inhibits cell migration and that some ADAM7 mutations alleviate
this, which might suggest that these mutations might be causing a loss of function effect.
To further our functional analysis of ADAM gene somatic alterations, we next focused on
ADAM29 which was found to be somatically mutated in over 15% of melanoma cases
(Table 1) making it the most highly mutated ADAM in this screen. Several criteria suggest
ADAM29 to also be a driver in melanoma (1) ADAM29 has previously been shown to harbor
somatic mutations in other cancer types (Table 2), (2) the observed mutations in ADAM29
are significantly higher to that expected by chance (p= 7.73E-08) (3) 14 non-synonymous
(N) and 0 synonymous (S) somatic mutations were identified in ADAM29, yielding a N:S
ratio of 14:0, which is significantly higher than the N:S ratio of 2:1 predicted for non-
selected passenger mutations (Sjoblom, et al., 2006) (P < 0.003) and (4) SIFT analysis
shows that seven of the 14 alterations in ADAM29 would affect its protein function (Supp.
Table S8).
On this basis, we chose to functionally evaluate some of the mutations identified in
ADAM29 as well. Somatic mutations in ADAM29 occurred mainly in the propeptide and
reprolysin domains (Supp. Figure S3B). As the reprolysin domain encodes the catalytic
portion of the protein and ADAM29 does not have protease activity, we decided to mainly
focus on the mutations found in the propeptide domain especially as an interesting cluster of
mutations was observed in this domain involving the p.E111K; p.S112F and p.S115F
alterations (Supp. Figure S3B).
To determine whether mutations in ADAM29 affected cell growth, we created stable pooled
clones expressing wild-type ADAM29 and seven tumor derived mutants (p.E111K,
p.S112F, p.S115F, p.E176K, p.I257F, p.G434D and p.E503K) in A375 cells, which were
shown to harbor wild-type ADAM29 (Supp. Table S9). A similar expression level of the
ADAM29 constructs was observed (Supp. Figure S7A). Expression of wild-type or mutant
ADAM29 did not affect the growth rate of A375 cells in tissue culture (Supp. Figure S7B).
In contrast, expression of the various ADAM29 mutants substantially increased cell
adhesion to collagen I and IV compared to cells expressing wild-type ADAM29 (P < 0.005,
t-test (Figure 3). Furthermore, five of the ADAM29 mutants (p.S112E, p.S115F, p.I257F,
p.G434D and p.E503K) showed significantly increased adhesion compared to wild type
ADAM29 to collagen II (P < 0.005, t-test (Figure 3). Binding to other extracellular matrix
Wei et al. Page 6
Hum Mutat. Author manuscript; available in PMC 2012 June 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
proteins such as fibronectin, laminin, tenascin and vitronectin showed some differential
binding between wild type and some of the ADAM29 mutants, but this was not as striking
as the binding to collagen I, II and IV (Supp. Figure S8).
DISCUSSION
We have performed the first systematic mutational analysis of the ADAMs gene family in
any human cancer type leading to the discovery of two frequently mutated ADAM genes,
ADAM7 and ADAM29. The somatic mutations identified in this study were confirmed by
multiple PCR and sequencing reactions. The mutations are novel and multiple mini-hotspot
alterations were identified in ADAM7. The changes in ADAM7 and ADAM29 affect highly
conserved residues. Our in silico analysis predicted that some of the mutated residues in
ADAM7 and ADAM29 would affect tumorigenic phenotypes of melanoma cells. This was
experimentally tested by cloning the relevant nucleotide alterations into ADAM7 as well as
ADAM29 cDNA. Functional assays confirmed that four of the mutations in ADAM7
(p.H243Y, p.M359I, p.E639K and p.S703N) have altering effects on the wild-type protein
function. Specifically, although cells expressing wild-type ADAM7 adhere to collagen IV
and laminin, the four mutated proteins reduce this ability significantly. Intriguingly, in
contrast to ADAM7, seven of the ADAM29 alterations (p.E111K, p.S112F, p.S115F,
p.E176K, p.I257F, p.G434D and p.E503K) increase the adhesion of melanoma cells to
collagen I and collagen IV, compared to wild-type ADAM29. These results emphasize the
need to test the role of each ADAM and its related mutations in an individual manner to
precisely define its functional role in cancer.
ADAM enzymes are zinc endopeptidases and contain a conserved zinc binding motif within
the reprolysin family zinc metallopeptidase domain (PF01421). Of all the presumed
functional human ADAM genes, 13 encode proteins that possess the characteristic
reprolysin-type active site (HEXGHXXGXXHD) in the metalloproteinase domain followed
downstream by the "Met turn” a key signature of metzincin enzymes (Bode, et al., 1993),
indicating functional proteolytic capability (Edwards, et al., 2008). Several ADAM family
members (including ADAM2, ADAM11, ADAM18, ADAM23 and ADAM32) lack all
three conserved histidines found within the zinc-binding motif which prevents zinc binding
and proteolytic activity. ADAM7 contains the “Met turn” as well as the three conserved
histidines, but is missing a glutamic acid in the second position of the motif, which is one of
the critical features in the Zn-binding active site (Supp. Figure S9). This suggests that the
metalloproteinase domain in ADAM7 may play roles in protein folding and protein–protein
interactions rather than cleaving components of extracellular matrix (Lopez-Otin and Bond,
2008). Interestingly, one of the ADAM7 mini-hotspot alterations discovered in our study
occurs at the Met-Turn (p.M359I), which as mentioned above is highly conserved
throughout the ADAM gene family, suggesting that this mutation would have substantial
functional effects on the protein.
A role in signal transduction of this ADAM gene is further supported by the fact that the
cytoplasmic domain of ADAM7 includes a phosphorylation site and a Src homology region
3 (SH3) binding domain. In particular, the motif LKQVQSP is recognized by those SH3
domains with non-canonical class II recognition specificity and the motif QVQSPPT is
predicted as a proline-directed kinase phosphorylation site in higher eukaryotes.
Interestingly, the p.S703N mutation is found in this location and might therefore be involved
in signalling.
Indeed, many ADAM cytoplasmic domains contain serine and proline residues, with
ADAM7 containing the consensus class I (RXXPXXP) and class II (PXXPXR) ligands for
interaction with SH3 domains of various intracellular proteins (Lopez-Otin and Hunter,
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2010; Seals and Courtneidge, 2003). These motifs also exist in other ADAM family
members such as ADAM1, ADAM15 and ADAM17 but their positions as well as the
neighboring sequences are different among the diverse ADAMs. It is therefore possible that
each ADAM could form a unique complex of cytoplasmic proteins through specific protein-
protein interactions.
Bioinformatics analysis of the ADAM7 and ADAM29 mutations was performed based on
sequence homology to other ADAM proteins in the family or in other species (Supp. Figure
S10) (Ruan, et al., 2008). Both the p.E639K and p.S703N mutations in ADAM7 were
outside of known existing protein family domains that were present in ADAM7 and were
not significantly evolutionarily conserved (Ng and Henikoff, 2003). It must be noted that
domains, such as the Reprolysin, ADAM_CR, Pep_M12B_propep have more conserved
residues among the different protein family members (Finn, et al., 2008). The most proximal
annotated domain to the two mutations is the transmembrane domain, which demarks how
the protein is situated in the plasma membrane of the cell. The locations of the p.E639K and
p.S703N mutations fall in the cytoplasmic region of the protein, which is highly variable
among the different species and family members and would probably affect protein
interactions within the cell, potentially altering intracellular signaling.
Several cancer genome wide studies (Jones, et al., 2008; Sjoblom, et al., 2006; Wood, et al.,
2007) clearly show that the cancer genetic landscape is made up of few genes that are
frequently mutated (cancer `mountain' genes) and a much larger number of genes that are
infrequently mutated (cancer `hill' genes) (Jones, et al., 2008). One main challenge is to
decipher which of the discovered mutations have a functional role in cancer progression and
are thus `drivers' and which of the mutations are `passengers'. While no direct inhibitors of
ADAM genes have reached clinical development yet, targeting altered ADAM-mediated
effector pathways has very recently entered clinical development: for example, targeting
ADAM17-mediated ligand cleavage to inhibit Erb receptor signaling through inhibition of
its secretase activity, or ADAM10 regulated Notch signaling are prime examples for such
efforts. The novel gamma secretase inhibitor RO4929097 (Tolcher, et al., 2010) or the
Notch inhibitor MK0752 (Deangelo, et al., 2010) have recently completed phase I clinical
trials. As we find that several of the novel alterations have a functional effect on the protein
suggesting that these are indeed drivers in melanoma, additional research on the role of the
gene family in human cancers might discover novel therapeutic avenues.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Mutant ADAM7 modulates cell adhesion. Adhesion properties of Mel-STR cells
overexpressing either the wild-type or mutant ADAM7 forms were assessed using the ECM
Cell Adhesion Array kit. Collagen IV (COLIV), laminin (LN), (n=2).
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Figure 2.
Effects of ADAM7 mutation on cell migration. (A) Mel-STR cells overexpressing wild-type
or mutant ADAM7 were seeded in Boyden chambers and assessed for their migration
abilities. Graph indicates the number of cells that migrated 24 hrs after seeding (n=3). (B)
Representative pictures of migrated cells.
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Figure 3.
Mutant ADAM29 modulates cell adhesion on collagen I, II and IV. Adhesion properties of
A375 cells overexpressing either the wild-type or mutant ADAM29 forms were assessed
with the ECM Cell Adhesion Array kit. collagen (COL), wild type (WT) (n=2).
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